Derivation Web

source_be4b3a414a2b42e0

by researka:v2 · 2026-06-29 05:57:50.723847+04:00

{"contradictions": ["Positive study-level signals are summarized in the safety outcome class; null signals are not the dominant direction in any outcome class; negative signals are not the dominant direction in any outcome class; mixed or heterogeneous signals are summarized in the contextual adjacent evidence, cardiometabolic, safety and comorbidity, and longevity outcome classes. The paper therefore interprets the corpus as a tiered evidence profile rather than as a single pooled effect.", "The conclusion is that SGLT2 inhibitor should be treated as a bounded geroscience hypothesis: the retained clinical and adjacent evidence profile defines the scope for targeted testing, while mixed and null findings limit any unqualified anti-aging claim.", "The direct evidence establishes what has been observed in human or adjacent clinical settings. The mechanistic evidence helps explain why an effect might be plausible, but it does not by itself establish the size, durability, or safety of a human healthspan effect.", "The study-level structure also prevents selective emphasis. Supportive, null, mixed, and adverse findings remain visible in the same manuscript, allowing the reader to distinguish evidential breadth from evidential certainty.", "Contextual Adjacent Evidence: n=6; claims=451; mixed signal in 3/6 sources | directness: 2 direct; 3 indirect; 1 review; main limitation: directionally heterogeneous.", "Several within-corpus tensions warrant explicit acknowledgement. First, on the indirectness gap axis, the two direct trials (Nassif 2021; Spertus 2022) must be read separately from the four indirect or review-level sources (Khanna 2026; Loutati 2026; Ryan 2018; Chen 2021); the curated excerpts do not support pooling direct and indirect evidence into a single effect estimate, and the evidence synthesis preserves that separation. Second, on the null vs positive axis, Loutati 2026 (positive on contextual other, observational) is in partial conflict with Chen 2021 (null on contextual other, preclinical), and the conflict is partially explained by endpoint layer (clinical event rates versus plaque histologic indices) and partially by study design (cohort versus murine experiment); readers should not interpret Chen 2021 as a refutation of Loutati 2026 without acknowledging that the two sources measure different things. Third, the directionality disagreement between Nassif 2021 (negative) and Spertus 2022 (unclear) within the same direct-RCT stratum cannot be resolved from the curated excerpts alone and is a genuine boundary condition of the present synthesis. Finally, Ryan 2018 — the only source explicitly positioned as a real-world comparative-effectiveness meta-analysis of four observational databases — supplies qualitative framing without extractable p-values in the curated excerpts, so its contribution to the contextual other class is contextual rather than quantitative; future updates should re-extract Ryan 2018 numerics before drawing comparative-effectiveness inferences. Across the corpus, the contextual other outcome class is the most numerate stratum of the SGLT2 inhibitor corpus but also the most internally heterogeneous, and any downstream anti-aging claim that rests on it must specify which sub-stratum (symptoms, structure, plaque biology, real-world events) is being invoked.", "Safety remains a separate Results slice for SGLT2 inhibitor (n=1; claims=11; positive signal in 1/1 sources; 1 review; single-source slice; hypothesis-generating) and is not pooled into adjacent endpoint classes. Nassif 2021 (NCT03030235) is a direct multicenter RCT in HFpEF reporting a constellation of p-values (P = 0.001, P = 0.003, P = 0.026, P = 0.007, P = 0.009, P = 0.03, P = 0.046, P = 0.06, P = 0.01) but with the source-coded direction flagged as 'negative,' meaning the primary functional endpoint did not deliver the anticipated benefit despite favorable signals in secondary biomarker readouts. By contrast, Metabolism to Microcirculation the Multifaceted 2026 catalogs vasoprotective mechanisms — dapagliflozin improving endothelial mitochondrial respiration in cell culture and murine models — that would predict hemodynamic and microcirculatory gains in vivo. The disagreement is not a contradiction but an evidence-type mismatch: preclinical and biomarker evidence is permitted to look unambiguously positive while the matched human functional RCT reads null or unfavorable. The boundary condition is the level of the outcome being measured — molecular microcirculatory flux, which the mechanistic review captures, is not equivalent to patient-reported or clinician-assessed functional status captured in HFpEF trials, a surrogate-vs-hard-outcome caution that aligns with Ioannidis 2005. What would resolve the tension is a human RCT powered on hard composite endpoints (mortality, hospitalization) rather than on biomarker surrogates or KCCQ-style symptom scores, ideally with prespecified microcirculatory substudies to confirm mechanistic engagement alongside clinical benefit.", "The longevity translation is the most fragile inference in the corpus. E 2026 — classified under the longevity outcome class — reports the HF-hospitalization pooled HR 0.65 (95% CI 0.59-0.72) finding but is anchored on indirect observational evidence and codes direction as 'unclear' on longevity per se. The mechanistic scaffolding (Metabolism to Microcirculation the Multifaceted 2026 on endothelial mitochondrial respiration; Chen 2021 on plaque instability in murine models) supports plausibility but is model-organism and biomarker evidence, not human mortality or healthspan evidence. This invokes the general caution registered by Ioannidis 2005 — surrogate endpoint shifts do not guarantee hard-outcome validity. The boundary condition is straightforward: SGLT2 inhibitors have credible mechanistic grounds to influence longevity-relevant biology (vascular aging, cardiorenal hemodynamics, metabolic substrate handling) but the sources in this corpus do not contain a human RCT with mortality or lifespan as a primary endpoint. The 'approximately one-third' reduction in HF hospitalization is encouraging but is not equivalent to a one-third reduction in mortality, and even E 2026's HR should not be re-stated as a longevity claim. Resolution would require either (a) a long-horizon RCT with mortality as the primary endpoint, or (b) high-quality individual-participant-data meta-analyses of completed trials with extended mortality follow-up. Until then, the appropriate hedge — and the one this synthesis adopts — is that the SGLT2-inhibitor anti-aging case is mechanistically coherent and clinically promising in selected hard outcomes, but its longevity translation in humans remains unestablished by the sources in hand.", "Mechanistically, the longevity signal in E 2026 rests on the same cardiovascular substrate that has been documented for SGLT2 inhibitors in mechanistic human studies and in clinical RCTs of heart failure outcomes: reduced preload, natriuresis, and improved ventricular loading conditions translate into fewer hospitalisation events, which in turn may bear on cumulative morbidity burden. The source is, however, framed as an observational cohort and is therefore best read as supporting contextual evidence rather than as a primary mechanistic demonstration. Because the outcome class is longevity rather than cardiovascular hospitalisation per se, the pathway connecting reduced HF admissions to longevity extension remains inferential. The mechanistic substrate underlying this functional finding is plausibly cardioprotective, but the source itself does not adjudicate the magnitude of any survival extension."], "limitations": ["This is an agent-assisted evidence map, not a PRISMA-complete systematic review or clinical guideline.", "It is not PROSPERO-registered and should not be read as medical advice.", "Public sidecars expose citation traces and extraction status; empty fields mean not extracted, not assumed absent."], "publication_id": "89c570cf-7f20-49de-a349-6ab8241f2855", "screening": {"excluded": 0, "exclusion_reasons": ["No PRISMA full-text exclusion-stage filter was applied."], "flow": ["identified", "screened", "excluded_with_reasons", "included"], "identified": 12, "included": 12, "included_or_retained": 12, "screened": 12, "wording": "12 candidate receipts retained after source retrieval, deduplication, and topic filtering. This is an evidence-map screening trace, not a PRISMA full-text exclusion audit."}}

{
  "researka_object_type": "publication_sidecar",
  "researka_publication_id": "89c570cf-7f20-49de-a349-6ab8241f2855",
  "researka_submission_id": "b1deb58f-6d4a-4194-a2b6-e27204330171",
  "sidecar_name": "contradiction_map.json",
  "sidecar_url": "https://api.researka.org/publications/89c570cf-7f20-49de-a349-6ab8241f2855/sidecars/contradiction_map.json"
}